IRIS
CONTEDUCA, VINCENZA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.530
NA - Nord America 840
AS - Asia 66
SA - Sud America 6
AF - Africa 3
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 2.451
Salva come PNG Salva come JPEG
Nazione #
IE - Irlanda 1.080
US - Stati Uniti d'America 837
SE - Svezia 264
IT - Italia 98
CN - Cina 43
UA - Ucraina 24
GB - Regno Unito 19
FI - Finlandia 13
DE - Germania 11
IN - India 8
ES - Italia 5
CL - Cile 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AU - Australia 3
TR - Turchia 3
BD - Bangladesh 2
CO - Colombia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
FR - Francia 2
GR - Grecia 2
HK - Hong Kong 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
VN - Vietnam 2
CA - Canada 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
IQ - Iraq 1
JP - Giappone 1
LT - Lituania 1
MD - Moldavia 1
NL - Olanda 1
NO - Norvegia 1
NP - Nepal 1
PK - Pakistan 1
RU - Federazione Russa 1
SA - Arabia Saudita 1
SM - San Marino 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 2.451
Salva come PNG Salva come JPEG
Città #
Dublin 1.078
Nyköping 208
Chandler 146
Princeton 128
Wilmington 126
Ashburn 58
Des Moines 23
Jacksonville 15
New York 13
Nanjing 11
London 10
Nocera Inferiore 10
Helsinki 9
Norwalk 9
Trento 9
Dearborn 7
Beijing 5
Madrid 5
Potenza 5
Pune 5
Shanghai 5
Stevenage 5
Bari 4
Cagliari 4
Foggia 4
Santa Maria a Monte 4
Washington 4
Aprilia 3
Houston 3
Palermo 3
Ravenna 3
Redmond 3
San Mateo 3
Bitonto 2
Bolton 2
Changsha 2
Chicago 2
Clearwater 2
Detva 2
Hanover 2
Hebei 2
Milan 2
Nanchang 2
Reston 2
Rome 2
Santiago de los Caballeros 2
Sétif 2
Tianjin 2
Viadana 2
Zhengzhou 2
Adliswil 1
Andover 1
Ann Arbor 1
Athens 1
Auburn 1
Barsinghausen 1
Basra 1
Borgo Maggiore 1
Brescia 1
Brno 1
Buffalo 1
Bussolengo 1
Calitri 1
Central 1
Cesena 1
Changchun 1
Chestnut Hill 1
Chisinau 1
Desio 1
Dong Ket 1
Forlimpopoli 1
Geislingen an der Steige 1
Groningen 1
Guangzhou 1
Hangzhou 1
Hanoi 1
Islamabad 1
Jalandhar 1
Jinan 1
Kathmandu 1
Kemerovo 1
Kowloon 1
Kunming 1
Lappeenranta 1
Las Vegas 1
Monte San Pietro 1
Montespertoli 1
Naples 1
North Brunswick 1
Nuremberg 1
Pittsburgh 1
Pretoria 1
Redwood City 1
Reghin 1
San Francisco 1
Seattle 1
Sydney 1
Taipei 1
Tampa 1
Taranto 1
Totale 2.012
Salva come PNG Salva come JPEG
Nome #
Pathophysiology of HCV-Related cryoglobulinemic vasculitis: molecular, immunological and clinical analysis 122
T cell receptor variable β gene repertoire in liver and peripheral blood lymphocytes of chronically hepatitis C virus-infected patients with and without mixed cryoglobulinaemia. 62
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 57
Interleukin 28B Gene Polymorphisms in Hepatitis C Virus-related Cryoglobulinemic Vasculitis 46
B-cell frequency in hepatitis C virus-related mixed cryoglobulinemia 43
Anogenital lichen sclerosus et atrophicus lesions in a case series of cancer patients on immunotherapy. 39
Axitinib after Sunitinib in metastatic renal cancer: Preliminary results from Italian "Real-World" SAX Study 39
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. 38
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. 37
Barrett's esophagus and esophageal cancer: An overview 37
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. 37
Association among metabolic syndrome, inflammation, and survival in prostate cancer 36
Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage 36
Biological Evolution of Castration-resistant Prostate Cancer 35
Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide 35
H. pylori infection and gastric cancer: State of the art (Review) 34
Androgen receptor signaling pathways as a target for breast cancer treatment 33
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer 33
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer 33
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study 32
Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone 32
Barrett's esophagus and esophageal cancer: An overview 32
BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy 31
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 30
AR copy number and AR signaling-directed therapies in castration-resistant prostate cancer 30
Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer 29
Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis 28
Cell-free DNA as a diagnostic marker for cancer: Current insights 28
The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversy 26
PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer 26
Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis 26
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA. 25
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis 25
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 24
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation 22
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib 22
Safety and Clinical Outcomes of Abiraterone Acetate after Docetaxel in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme 22
Circulating tumor cells: Utopia or reality? 22
Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer 21
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: Results of the Italian Named Patient Programme 21
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone 21
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: Results of the Italian Named Patient Programme 21
Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone 21
Vitamin D status among long-term survivors of testicular cancer 21
In reply 21
Molecular mechanisms of resistance in testicular germ cell tumors - Clinical implications 21
Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review. 21
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. 20
Hepatitis C virus infection and mixed cryoglobulinemia 20
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma. 20
Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma 20
Persistent neutrophil to lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer 20
Metabolic syndrome as a peculiar target for management of prostate cancer patients 20
High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer 20
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. 20
Epigenetics in prostate cancer: clinical implications 20
Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage 19
Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone 19
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer 18
Conditional survival of patients treated with first-line chemotherapy for metastatic urothelial cancer 18
New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer. 18
Taxane-related nail toxicity 18
The emerging role of anti-angiogenic therapy in ovarian cancer (review) 18
Neuroendocrine differentiation in prostate cancer: Current and emerging therapy strategies 18
Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: A long-term study 18
Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy. 18
Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. 17
Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging. 17
The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment. 17
Role of DNA repair machinery and p53 in the testicular germ cell cancer: A review 17
Impact of cryoglobulinemic syndrome on the outcome of chronic hepatitis C virus infection: A 15-year prospective study 17
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer 17
Transarterial chemoembolization plus sorafenib: A sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: A randomized clinical trial 17
Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724–31 17
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus 17
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients 17
Erratum to: 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide [Eur J Nucl Med Mol Imaging, DOI 10.1007/s00259-015-3042-5] 17
Precancerous colorectal lesions (Review) 17
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone 17
Targeted radioactive therapy for prostate cancer 17
Plasma Androgen Receptor in Prostate Cancer. 17
Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program 16
Re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680–7 16
Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer. 16
Immunotherapy for prostate cancer: Where we are headed 16
Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents 16
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. 16
Prognostic value of 18F–choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide 16
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer 16
The potential use of urine cell free DNA as a marker for cancer 16
Urinary RNA-based biomarkers for prostate cancer detection 16
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone 16
Genome-wide plasma DNA methylation features of metastatic prostate cancer. 16
Talazoparib: a new biomarker-directed therapy in advanced prostate cancer 16
Molecular mechanisms of resistance in testicular germ cell tumors - Clinical implications 16
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer. 16
CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone 15
Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone 15
Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy 15
Immunotherapy for prostate cancer: Where we are headed 15
Totale 2.450
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.569
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.569
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201910 0 0 0 0 0 0 0 0 0 1 3 6
2019/202055 12 6 7 0 6 5 5 2 8 0 4 0
2020/202131 3 0 3 0 6 2 5 0 4 4 1 3
2021/2022856 4 2 3 1 371 15 25 50 102 104 17 162
2022/20231.723 186 31 86 25 47 109 3 71 1.117 15 19 14
2023/2024197 11 19 11 19 26 77 1 21 8 4 0 0
Totale 2.915